The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 358:742-743 February 14, 2008 Number 7
NextNext

Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Diehl, V.
-Related Article
by Fermé, C.
-PubMed Citation
To the Editor: Fermé et al. (Nov. 8 issue)1 and Diehl in the accompanying editorial2 question the possibility that chemotherapy alone is curative in early-stage Hodgkin's disease. We wish to draw attention to the reported experience with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) chemotherapy in childhood Hodgkin's disease in Uganda.3,4 Lacking resources for radiotherapy, we treated 48 children with six cycles of MOPP, the standard of care in the 1970s. Of these 48 children, 42 had complete responses, and the overall survival rate at 10 years was 67%. All 18 patients with stages I to IIIA disease had complete responses; . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.